# US 2006/0051300 A1 · Formulations and methods for treating rhinosinusitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051300 A1
- Document ID: US20060051300A1
- Status: Published application
- Kind: A1
- Application number: 11/250,925
- Filed: 2005-10-14
- Published: 2006-03-09
- Earliest claimed: 2004-03-29
- Assignees: Merck Patent GmbH
- Inventors: Imtiaz Chaudry
- Web page: https://patentgrep.com/patent/US20060051300A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/0043: {Nose}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61L 2/07: Steam
- A61L 2/081: Gamma radiation
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61K 9/10: Dispersions; Emulsions
- A61L 2103/05: Living organisms or biological materials
- A61L 2103/10: Medicinal preparations other than biologicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.

## Claims

### Claim 1

A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, comprising:
a) a therapeutically effective amount of a steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns; wherein said formulation is suitable for administration to the nasal-paranasal mucosa; and
b) an antifungal agent, wherein the amount of the antifungal agent is from about 0.5 to 150 mg.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the formulation comprises about 1 to about 700 mcg of a steroidal anti-inflammatory, and wherein the steroidal anti-inflammatory is fluticasone, beclomethasone, pharmaceutically acceptable derivatives thereof, or combinations thereof.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the steroidal anti-inflammatory is fluticasone propionate having the following particle size distribution profile:
i. about 10% of the fluticasone propionate particles have a particle size of less than 0.70 microns;
ii. about 25% of the fluticasone propionate particles have a particle size of less than 1.30 microns;
iii. about 50% of the fluticasone propionate particles have a particle size of less than 2.5 microns;
iv. about 75% of the fluticasone propionate particles have a particle size of less than 4.0 microns;
v. about 90% of the fluticasone propionate have a particle size of less than 6.0 microns; and,
vi. greater than 90% or about 100% of the fluticasone propionate particles have a particle size of less than 10 microns.

### Claim 4 (depends on 3)

The nasal pharmaceutical formulation of claim 3, wherein the fluticasone has the following particle size distribution profile:
i. about 10% of the fluticasone particles have a particle size of less than 0.40 microns;
ii. about 25% of the fluticasone particles have a particle size of less than 0.80 microns;
iii. about 50% of the fluticasone particles have a particle size of less than 1.60 microns;
iv. about 75% of the fluticasone particles have a particle size of less than 3.0 microns; and
v. about 90% of the fluticasone particles have a particle size of less than 5.30 microns.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the steroidal anti-inflammatory is beclomethasone or a pharmaceutically acceptable derivative thereof having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.75 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 2.0 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.5 microns; and v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.0 microns.

### Claim 6 (depends on 5)

The nasal pharmaceutical formulation of claim 5, wherein the beclomethasone has the following particle size distribution profile:
i. about 10% of the beclomethasone particles have a particle size of less than 0.50 microns;
ii. about 25% of the beclomethasone particles have a particle size of less than 1.0 microns;
iii. about 50% of the beclomethasone particles have a particle size of less than 1.5 microns;
iv. about 75% of the beclomethasone particles have a particle size of less than 2.5 microns; and
v. about 90% of the beclomethasone particles have a particle size of less than 4.0 microns.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein the formulation comprises an aqueous suspension that is deliverable via an atomizing device.

### Claim 8 (depends on 7)

The formulation of claim 7, wherein the atomizing device comprises a metered dose spray pump.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the formulation is suspended in a liquid propellant.

### Claim 10 (depends on 1)

The formulation of claim 1, wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

### Claim 11 (depends on 1)

The formulation of claim 1, further comprising about 20 to about 70 mg of fluconazole or itraconazole.

### Claim 12 (depends on 11)

The formulation of claim 11, wherein the formulation comprises about 25 to about 50 mg of fluconazole or itraconazole.

### Claim 13 (depends on 12)

The formulation of claim 12, wherein the formulation comprises about 30 mg of fluconazole or itraconazole.

### Claim 14 (depends on 11)

The formulation of claim 11, wherein the formulation comprises about 7.5 to about 15 mg of amphotericin β.

### Claim 15 (depends on 1)

The formulation of claim 1, further comprising an antibiotic, antiviral agent, or combinations thereof.

### Claim 16 (depends on 15)

The formulation of claim 15, wherein the antibiotic is one or more of Amikacin, Azithromycin, Aztreonan, Cefazolin, Cefepine, Cefonicid, Cefaperazone, Cefotaxime, Cefotetan, Cefoxitin, Ceftazidime, Ceftizoxime, Ceftriaxone, Cefuroxime, Cephapirin, Ciprofloxacin, Clindamycin, Doxycycline, Erythromycin Lactobionate, Gentamicin, Kanamycin, Linezolid, Mezlocillin, Mupirocin, Nafcillin, Netilmicin, Neomycin, Oxacillin, Paromomycin, Piperacillin, Streptomycin, Ticarcillin, Tobramycin, or Vancomycin.

### Claim 17 (depends on 1)

The formulation of claim 1, wherein the formulation is a sterile aqueous suspension or aqueous solution.

### Claim 18

A nasal spray formulation comprising:
an aqueous suspension having
a) about 0.005% to about 5% by weight of a steroidal anti-inflammatory, the steroidal anti-inflammatory comprising fluticasone, beclomethasone, pharmaceutically acceptable derivatives thereof, or combinations thereof having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns; wherein said formulation is suitable for administration to the nasal-paranasal mucosa; and
b) an antifungal agent, wherein the amount of the antifungal agent is from about 0.5 to 150 mg.

### Claim 19 (depends on 18)

The nasal spray formulation of claim 18, wherein the wherein the formulation is deliverable via a metered dose spray pump.

### Claim 20 (depends on 19)

The nasal spray formulation according to claim 19, wherein ambient air is a propelling agent for delivering each spray of the metered-dose spray pump.

### Claim 21 (depends on 18)

The nasal spray formulation of claim 18, further comprising a preservative, suspending agent, wetting agent, buffer, diluent, or combinations thereof.

### Claim 22 (depends on 18)

The nasal spray formulation of claim 18, wherein the formulation further comprises one or more of the following compounds: (a) microcrystalline cellulose; (b) carboxymethyl cellulose sodium; (c) dextrose; (d) benzalkonium chloride; (e) polysarbate 80; or (f) phenylethyl alcohol.

### Claim 23 (depends on 18)

The nasal spray formulation of claim 18, wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

### Claim 24 (depends on 18)

The nasal spray formulation of claim 18, wherein the steroidal anti-inflammatory is fluticasone having the following particle size distribution profile:
i. about 10% of the fluticasone particles have a particle size of less than 0.40 microns;
ii. about 25% of the fluticasone particles have a particle size of less than 0.80 microns;
iii. about 50% of the fluticasone particles have a particle size of less than 1.60 microns;
iv. about 75% of the fluticasone particles have a particle size of less than 3.0 microns; and
v. about 90% of the fluticasone particles have a particle size of less than 5.30 microns.

### Claim 25 (depends on 18)

The nasal spray formulation of claim 18, wherein the steroidal anti-inflammatory is beclomethasone having the following particle size distribution profile:
i. about 10% of the beclomethasone particles have a particle size of less than 0.50 microns;
ii. about 25% of the beclomethasone particles have a particle size of less than 1.0 microns;
iii. about 50% of the beclomethasone particles have a particle size of less than 1.5 microns;
iv. about 75% of the beclomethasone particles have a particle size of less than 2.5 microns; and
v. about 90% of the beclomethasone particles have a particle size of less than 4.0 microns.

### Claim 26 (depends on 18)

The nasal spray formulation of claim 18, further comprising neomycin sulfate.

### Claim 27

A method of treating fungus-induced rhinosinusitis in a mammal, said method comprising the steps of applying to the mammal's nasal-paranasal mucosa a formulation comprising:
a) a therapeutically effective amount of a steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.90 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 1.6 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 3.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 6.2 microns; and
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 10.0 microns; wherein said formulation is suitable for administration to the nasal-paranasal mucosa; and
b) an antifungal agent, wherein the amount of the antifungal agent is from about 0.5 to 150 mg.

### Claim 28 (depends on 27)

The method of claim 27, wherein the steroidal anti-inflammatory is fluticasone having the following particle size distribution profile:
i. about 10% of the fluticasone particles have a particle size of less than 0.40 microns;
ii. about 25% of the fluticasone particles have a particle size of less than 0.80 microns;
iii. about 50% of the fluticasone particles have a particle size of less than 1.60 microns;
iv. about 75% of the fluticasone particles have a particle size of less than 3.0 microns; and
v. about 90% of the fluticasone particles have a particle size of less than 5.30 microns.

### Claim 29 (depends on 27)

The method of claim 27, wherein the steroidal anti-inflammatory is beclomethasone having the following particle size distribution profile:
i. about 10% of the beclomethasone particles have a particle size of less than 0.50 microns;
ii. about 25% of the beclomethasone particles have a particle size of less than 1.0 microns;
iii. about 50% of the beclomethasone particles have a particle size of less than 1.5 microns;
iv. about 75% of the beclomethasone particles have a particle size of less than 2.5 microns; and
v. about 90% of the beclomethasone particles have a particle size of less than 4.0 microns.

### Claim 30 (depends on 27)

The method of claim 27, wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

### Claim 31 (depends on 27)

The method of claim 27, formulation is applied via a metered-dose, manual pump spray unit.

### Claim 32 (depends on 31)

The method of claim 31, wherein the formulation is administered to the mammal as one spray in each nostril from 1 to about 10 times per day.
